01 6Lo Loestrin
02 3Myfembree/Ryeqo
Main Therapeutic Indication : Urology
Currency : USD
2020 Revenue in Millions : 356
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Urology
Currency : USD
2021 Revenue in Millions : 437
2020 Revenue in Millions : 356
Growth (%) : 23
Norethindrone Acetate/Ethinyl estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2017 Revenue in Millions : 459
2016 Revenue in Millions : 404
Growth (%) : 14
Norethindrone Acetate/Ethinyl Estradiol
Main Therapeutic Indication : Sexual Health
Currency : USD
2018 Revenue in Millions : 528
2017 Revenue in Millions : 459
Growth (%) : 15%
Norethindrone Acetate/Ethinyl Estradiol
Main Therapeutic Indication : Contraception
Currency : USD
2016 Revenue in Millions : 404
2015 Revenue in Millions : 350
Growth (%) : 15
Main Therapeutic Indication : Urology
Currency : USD
2019 Revenue in Millions : 589
2018 Revenue in Millions : 528
Growth (%) : 12
Main Therapeutic Indication : Women's Healthcare
Currency : USD
2021 Revenue in Millions : 8
2020 Revenue in Millions : 0
Growth (%) : New Launch in 2021
Main Therapeutic Indication : Women's Health
Currency : USD
2022 Revenue in Millions : 25
2021 Revenue in Millions : 8
Growth (%) : 234
Main Therapeutic Indication : Women's Health
Currency : USD
2023 Revenue in Millions : 60
2022 Revenue in Millions : 32
Growth (%) : 110
LOOKING FOR A SUPPLIER?